HRP20080614T3 - Polymorphic forms of a gabaa agonist - Google Patents
Polymorphic forms of a gabaa agonistInfo
- Publication number
- HRP20080614T3 HRP20080614T3 HR20080614T HRP20080614T HRP20080614T3 HR P20080614 T3 HRP20080614 T3 HR P20080614T3 HR 20080614 T HR20080614 T HR 20080614T HR P20080614 T HRP20080614 T HR P20080614T HR P20080614 T3 HRP20080614 T3 HR P20080614T3
- Authority
- HR
- Croatia
- Prior art keywords
- polymorphic forms
- gabaa agonist
- gabaa
- agonist
- peak
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 238000002083 X-ray spectrum Methods 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 230000005855 radiation Effects 0.000 abstract 2
- -1 compound gaboxadol monohydrate Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402118.4A GB0402118D0 (en) | 2004-01-30 | 2004-01-30 | Polymorphic forms of a GABAA agonist |
| PCT/GB2005/000288 WO2005073237A2 (en) | 2004-01-30 | 2005-01-28 | Polymorphic forms of a gabaa agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080614T3 true HRP20080614T3 (en) | 2009-01-31 |
Family
ID=31971783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080614T HRP20080614T3 (en) | 2004-01-30 | 2008-11-26 | Polymorphic forms of a gabaa agonist |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US7262300B2 (ko) |
| EP (2) | EP1713813B1 (ko) |
| JP (1) | JP4917440B2 (ko) |
| KR (1) | KR101210361B1 (ko) |
| CN (1) | CN1914212B (ko) |
| AR (1) | AR047511A1 (ko) |
| AT (1) | ATE414088T1 (ko) |
| AU (1) | AU2005209473B2 (ko) |
| BR (1) | BRPI0506858A (ko) |
| CA (1) | CA2554536C (ko) |
| CO (1) | CO5700743A2 (ko) |
| CY (1) | CY1108647T1 (ko) |
| DE (1) | DE602005010975D1 (ko) |
| DK (1) | DK1713813T3 (ko) |
| DO (1) | DOP2005000013A (ko) |
| EA (1) | EA009413B1 (ko) |
| EC (1) | ECSP066735A (ko) |
| ES (1) | ES2314613T3 (ko) |
| GB (2) | GB0402118D0 (ko) |
| HK (1) | HK1096547A1 (ko) |
| HR (1) | HRP20080614T3 (ko) |
| IL (1) | IL176863A0 (ko) |
| MA (1) | MA28364A1 (ko) |
| MX (1) | MXPA06008595A (ko) |
| MY (1) | MY139525A (ko) |
| NO (1) | NO20063843L (ko) |
| NZ (1) | NZ548191A (ko) |
| PE (1) | PE20050769A1 (ko) |
| PL (1) | PL1713813T3 (ko) |
| PT (1) | PT1713813E (ko) |
| SI (1) | SI1713813T1 (ko) |
| TW (1) | TWI345972B (ko) |
| UA (1) | UA87487C2 (ko) |
| WO (1) | WO2005073237A2 (ko) |
| ZA (1) | ZA200605307B (ko) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| DE102005004343A1 (de) * | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
| EP2292222A1 (en) * | 2005-01-28 | 2011-03-09 | H. Lundbeck A/S | Polymorphic Forms of a GABAA Agonist |
| CN101309667A (zh) | 2005-09-28 | 2008-11-19 | 奥里斯医学股份有限公司 | 治疗内耳疾病的药用合成物 |
| CN102093387B (zh) * | 2009-12-10 | 2012-07-25 | 天津泰普医药知识产权流转储备中心有限公司 | 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物 |
| WO2013087090A1 (en) | 2011-12-12 | 2013-06-20 | Auris Medical Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
| JP2018520189A (ja) * | 2015-07-17 | 2018-07-26 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ガボキサドールでの発達障害の処置方法 |
| EP4233861A3 (en) * | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| AU2017363598A1 (en) * | 2016-11-22 | 2019-05-23 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with flupirtine |
| US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| AU2018309049A1 (en) | 2017-08-04 | 2020-02-27 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
| MX2021003302A (es) | 2018-09-20 | 2021-05-13 | Ovid Therapeutics Inc | Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez. |
| KR20210110585A (ko) | 2018-11-21 | 2021-09-08 | 썰테고 테라퓨틱스 아이엔씨. | 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌 |
| KR20210105387A (ko) | 2018-12-17 | 2021-08-26 | 오비드 테라퓨틱스 인크. | 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용 |
| AU2020405060A1 (en) | 2019-12-18 | 2022-06-09 | Ovid Therapeutics Inc. | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome |
| EP4153549A2 (en) | 2020-05-20 | 2023-03-29 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) * | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4315934A (en) * | 1979-09-24 | 1982-02-16 | Sandoz Ltd. | Organic compounds |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4352731A (en) * | 1980-11-03 | 1982-10-05 | Occidental Research Corporation | Apparatus for selective wetting of particles |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| UA52661C2 (uk) * | 1996-06-14 | 2003-01-15 | Ново Нордіск А/С | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти |
| CA2385749A1 (en) | 1999-09-28 | 2001-04-05 | H. Lundbeck A/S | Melt granulated composition and modified release dosage form prepared from said composition |
| AR031473A1 (es) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| EP1399138B1 (de) | 2001-05-18 | 2006-02-08 | Lonza Ag | Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat |
| CA2447603A1 (en) | 2001-05-21 | 2002-11-28 | H. Lundbeck A/S | Granular preparations of gaboxadol |
| AU2002333157A1 (en) * | 2002-09-03 | 2004-03-29 | Naturon Limited | Compound for treatment of anxiety and methods of preparation and use thereof |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| PL1641456T3 (pl) | 2003-06-25 | 2010-08-31 | H Lundbeck As | Gaboksadol do leczenia depresji i innych zaburzeń afektywnych |
| AR045540A1 (es) * | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
| US20070032553A1 (en) | 2003-09-10 | 2007-02-08 | Mckernan Ruth | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| TW200528098A (en) | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| MXPA06015196A (es) | 2004-06-29 | 2007-03-15 | Lundbeck & Co As H | Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide. |
| GB0417558D0 (en) | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP2292222A1 (en) * | 2005-01-28 | 2011-03-09 | H. Lundbeck A/S | Polymorphic Forms of a GABAA Agonist |
| EP1863808A1 (en) | 2005-03-18 | 2007-12-12 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| EP1906953A4 (en) | 2005-04-29 | 2009-05-20 | Lundbeck & Co As H | FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL |
-
2004
- 2004-01-30 GB GBGB0402118.4A patent/GB0402118D0/en not_active Ceased
-
2005
- 2005-01-20 AR ARP050100210A patent/AR047511A1/es not_active Application Discontinuation
- 2005-01-21 TW TW094101857A patent/TWI345972B/zh not_active IP Right Cessation
- 2005-01-24 MY MYPI20050253A patent/MY139525A/en unknown
- 2005-01-27 PE PE2005000102A patent/PE20050769A1/es not_active Application Discontinuation
- 2005-01-28 WO PCT/GB2005/000288 patent/WO2005073237A2/en active Search and Examination
- 2005-01-28 EP EP05702040A patent/EP1713813B1/en active Active
- 2005-01-28 AU AU2005209473A patent/AU2005209473B2/en not_active Ceased
- 2005-01-28 CN CN2005800031615A patent/CN1914212B/zh active Active
- 2005-01-28 DK DK05702040T patent/DK1713813T3/da active
- 2005-01-28 CA CA2554536A patent/CA2554536C/en not_active Expired - Fee Related
- 2005-01-28 MX MXPA06008595A patent/MXPA06008595A/es active IP Right Grant
- 2005-01-28 GB GB0501847A patent/GB2410434A/en not_active Withdrawn
- 2005-01-28 PT PT05702040T patent/PT1713813E/pt unknown
- 2005-01-28 PL PL05702040T patent/PL1713813T3/pl unknown
- 2005-01-28 AT AT05702040T patent/ATE414088T1/de active
- 2005-01-28 SI SI200530521T patent/SI1713813T1/sl unknown
- 2005-01-28 BR BRPI0506858-4A patent/BRPI0506858A/pt not_active IP Right Cessation
- 2005-01-28 NZ NZ548191A patent/NZ548191A/en not_active IP Right Cessation
- 2005-01-28 DO DO2005000013A patent/DOP2005000013A/es unknown
- 2005-01-28 EA EA200601404A patent/EA009413B1/ru not_active IP Right Cessation
- 2005-01-28 DE DE602005010975T patent/DE602005010975D1/de active Active
- 2005-01-28 UA UAA200609410A patent/UA87487C2/ru unknown
- 2005-01-28 JP JP2006550301A patent/JP4917440B2/ja active Active
- 2005-01-28 EP EP08019457A patent/EP2042505A1/en not_active Withdrawn
- 2005-01-28 US US11/045,768 patent/US7262300B2/en active Active
- 2005-01-28 ES ES05702040T patent/ES2314613T3/es active Active
-
2006
- 2006-06-27 ZA ZA200605307A patent/ZA200605307B/en unknown
- 2006-07-13 IL IL176863A patent/IL176863A0/en unknown
- 2006-07-26 CO CO06073254A patent/CO5700743A2/es not_active Application Discontinuation
- 2006-07-28 EC EC2006006735A patent/ECSP066735A/es unknown
- 2006-07-28 KR KR1020067015417A patent/KR101210361B1/ko not_active IP Right Cessation
- 2006-08-22 MA MA29278A patent/MA28364A1/fr unknown
- 2006-08-29 NO NO20063843A patent/NO20063843L/no not_active Application Discontinuation
-
2007
- 2007-02-23 HK HK07102068A patent/HK1096547A1/xx unknown
- 2007-07-13 US US11/827,570 patent/US8236958B2/en active Active
-
2008
- 2008-11-26 HR HR20080614T patent/HRP20080614T3/xx unknown
- 2008-12-10 CY CY20081101439T patent/CY1108647T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080614T3 (en) | Polymorphic forms of a gabaa agonist | |
| NO20080784L (no) | Histondeacetylaseinhibitorer | |
| RS53415B (en) | NALMEFEN HYDROCHLORIDE DIHYDRATE | |
| EA200601274A1 (ru) | Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| RS52375B (en) | STABLE CRYSTALS OF 4-OXOCHINOLINE COMPOUND | |
| CY1116339T1 (el) | Πολυμορφικες μορφες ενος μακροκυκλικου αναστολεα hcv | |
| CY1111671T1 (el) | Ετεροκυκλικη ενωση | |
| CY1115163T1 (el) | Σπειροετεροκυκλικες ν-οξυπιπεριδινες ως ζιζανιοκτονα | |
| CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
| GEP20125523B (en) | Metabolites of (thio) carbamoyl-cyclohexane derivatives | |
| TWI368823B (en) | Coating compositions for use with an overcoated photoresist | |
| TWI340296B (en) | Coating compositions for use with an overcoated photoresist | |
| CY1113011T1 (el) | Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην | |
| RS52843B (en) | THE NEW IS THE HYDROGEN SULPHATE | |
| CY1114287T1 (el) | Νεα πυραζολο-4-ν-αλκοξυκαρβοξαμιδια ως μικροβιοκτονα | |
| GB0602430D0 (en) | Light for studio photography | |
| NO20050620L (no) | Nye 2-aryltiazol-forbindelser som PPARALPHA og PPARGAMA agonister | |
| GB0722483D0 (en) | High-molecular compounds and high-molecular luminescent devices made by using the same | |
| BRPI0814809A2 (pt) | Compostos di(arilamino)arílicos | |
| NO20076347L (no) | Nye regimer for orale monofasiske befruktningshindrene midler | |
| GB2440845B (en) | Methods of cementing with lightweight cement compositions | |
| HK1164114A1 (en) | Antidepressant containing heterocyclic compound having specific structure | |
| NO20035442D0 (no) | Pulverlakksammensetning | |
| EA200801365A1 (ru) | Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины | |
| EP2186352A4 (en) | CAPACITOR MICROPHONE USING CERAMIC PACKAGE WITH INTERIOR SURROUNDED WITH METAL OR CONDUCTIVE MATERIALS |